September 13, 2019 / 1:19 PM / a month ago

BRIEF-Genmab: Partner For Ofatumumab Presents Positive Results From Phase III Asclepios I, II Studies

Sept 13 (Reuters) - Genmab A/S:

* DETAILED RESULTS FROM PHASE III ASCLEPIOS I & II STUDIES OF OFATUMUMAB IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS PRESENTED AT ECTRIMS

* PARTNER FOR OFATUMUMAB, NOVARTIS, PRESENTED POSITIVE RESULTS FROM PHASE III ASCLEPIOS I AND II STUDIES

* NOVARTIS PLANS TO INITIATE SUBMISSIONS TO HEALTH AUTHORITIES BY END OF 2019

* BOTH ASCLEPIOS I AND II STUDIES MET THEIR PRIMARY ENDPOINTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below